Figure 1.
Thiazolidinediones and metformin are associated with improved survival of diabetic prostate cancer patients. Kaplan–Meier survival curves comparing ever-users and never-users are shown for thiazolidinediones (A), metformin (B), thiazolidinediones and/or metformin (C), insulins and insulin analogues (D), insulin secretagogues (E), and insulins or analogues and/or insulin secretagogues (F). The P values of the log-rank tests are as labeled.